GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (STU:ETF) » Definitions » Capex-to-Operating-Income

Elite Pharmaceuticals (STU:ETF) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Elite Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Elite Pharmaceuticals's Capital Expenditure for the three months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was €3.24 Mil.

Hence, Elite Pharmaceuticals's Capex-to-Operating-Income for the three months ended in Dec. 2023 was 0.00.


Elite Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Elite Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Capex-to-Operating-Income Chart

Elite Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.16 0.10 1.45

Elite Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Elite Pharmaceuticals's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Capex-to-Operating-Income falls into.



Elite Pharmaceuticals Capex-to-Operating-Income Calculation

Elite Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-5.358) / 3.707
=1.45

Elite Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 3.24
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elite Pharmaceuticals  (STU:ETF) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Elite Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals (STU:ETF) Business Description

Traded in Other Exchanges
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Elite Pharmaceuticals (STU:ETF) Headlines

No Headlines